Stock detail
Novavax (NVAX) stock price, chart, and key data
View Novavax stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Novavax
NVAX · XNAS
$11.25
-12.25%
-$1.57
Overnight $11.17 (-0.71%)
Key metrics
52-week range
$4.25 - $3.00
Close price
$12.82
Market cap
$2.1B
P/E ratio
-8.38
Beta
0.86
About the company
Novavax Inc
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.
Analyst rating summary
A current read on analyst sentiment from the insight feed.
Mean target
$10.75
2
Sell
/ 4
Recent calls
10/16/2026
Citi
Geoff Meacham
Sell · Price target $8.00
10/09/2026
Bank of America Securities
Alec Stranahan
Sell · Price target $8.00
08/06/2026
Cantor Fitzgerald
Pete Stavropoulos
Buy · Price target $18.00
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app